Articles related to TARGETED THERAPIES

An updated review of multiple myeloma management highlights revised high-risk definitions, anti-CD38-based quadruplet induction regimens, evolving maintenance strategies, and increasing use of CAR-T and bispecific immunotherapies across the disease continuum.

Emerging evidence suggests microbiome composition may be associated with immunotherapy response, toxicity, and outcomes in kidney cancer. Experts caution that inconsistent methodologies and limited reproducibility continue to challenge microbiome biomarker development.

A case-based application of FRESCO trial data positions fruquintinib as a third-line option in KRAS-mutant metastatic colorectal cancer, while emphasizing treatment decisions shift toward disease control and quality of life after multiple prior lines.

Talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% versus enzalutamide alone in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations, with a 3-year rPFS rate of 77% versus 56% in a 599-patient phase 3 trial.

Daraxonrasib, an oral RAS(ON) inhibitor, doubled overall survival and progression-free survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma across RAS-mutated and wild-type disease in a phase 3 trial.

A gynecologic oncologist reviews the current role of immune checkpoint inhibition across locally advanced and recurrent cervical cancer settings, including KEYNOTE-A18 survival data, key regulatory distinctions, and unanswered sequencing questions.